DekaBank Deutsche Girozentrale trimmed its holdings in Chemed Corporation (NYSE:CHE - Free Report) by 0.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 154,579 shares of the company's stock after selling 688 shares during the quarter. DekaBank Deutsche Girozentrale owned 1.06% of Chemed worth $92,676,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently modified their holdings of the business. Raymond James Financial Inc. bought a new stake in Chemed in the 4th quarter valued at $42,023,000. Bessemer Group Inc. increased its stake in shares of Chemed by 14.2% in the first quarter. Bessemer Group Inc. now owns 950 shares of the company's stock valued at $585,000 after buying an additional 118 shares in the last quarter. DAVENPORT & Co LLC acquired a new stake in shares of Chemed in the first quarter valued at $265,000. Park Place Capital Corp increased its stake in shares of Chemed by 71.2% in the first quarter. Park Place Capital Corp now owns 3,572 shares of the company's stock valued at $2,198,000 after buying an additional 1,486 shares in the last quarter. Finally, Mather Group LLC. increased its position in Chemed by 53.3% in the first quarter. Mather Group LLC. now owns 161 shares of the company's stock worth $99,000 after purchasing an additional 56 shares during the period. 95.85% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the company. Royal Bank Of Canada reiterated an "outperform" rating and issued a $640.00 price objective (down from $674.00) on shares of Chemed in a research report on Monday, June 30th. Bank of America reduced their target price on Chemed from $708.00 to $650.00 and set a "buy" rating on the stock in a report on Monday, June 30th. Finally, Wall Street Zen cut Chemed from a "buy" rating to a "hold" rating in a report on Saturday, July 5th.
View Our Latest Stock Report on Chemed
Chemed Stock Performance
NYSE CHE traded down $6.49 during trading on Thursday, hitting $465.08. The stock had a trading volume of 34,756 shares, compared to its average volume of 111,830. The company has a market capitalization of $6.80 billion, a PE ratio of 22.65, a P/E/G ratio of 2.24 and a beta of 0.50. The company's 50-day moving average price is $549.12 and its two-hundred day moving average price is $561.45. Chemed Corporation has a 12 month low of $457.44 and a 12 month high of $623.61.
Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The company reported $5.63 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.04. The firm had revenue of $646.94 million for the quarter, compared to analyst estimates of $641.78 million. Chemed had a return on equity of 27.58% and a net margin of 12.40%. The business's quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.20 EPS. As a group, equities analysts anticipate that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.
Chemed Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 17th. Investors of record on Thursday, May 29th were issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date was Thursday, May 29th. Chemed's payout ratio is presently 9.74%.
Insider Buying and Selling at Chemed
In related news, EVP Spencer S. Lee sold 1,500 shares of the business's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $577.99, for a total value of $866,985.00. Following the completion of the sale, the executive vice president directly owned 14,627 shares in the company, valued at $8,454,259.73. The trade was a 9.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kevin J. Mcnamara sold 1,500 shares of the business's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $576.45, for a total value of $864,675.00. Following the completion of the sale, the chief executive officer owned 101,197 shares of the company's stock, valued at $58,335,010.65. This trade represents a 1.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,500 shares of company stock valued at $2,598,450 over the last 90 days. 3.29% of the stock is currently owned by corporate insiders.
Chemed Profile
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading

Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.